Huntington's disease-like 2 (HDL2) closely resembles Huntington's disease (HD) in clinical and pathological features. Neurofilament light chain (NfL) is an important biomarker in HD research and holds potential in HDL2. To evaluate NfL's utility in HDL2, a comparative analysis among HDL2 (n = 12), HD (n = 9), and unaffected controls (n = 9) was conducted. Employing a cross-sectional design, NfL levels were assessed in blood plasma. Concentrations were notably elevated in both HD and HDL2 groups compared to controls. HD patients displayed higher NfL levels than HDL2, possibly reflecting disease duration differences. NfL effectively distinguished HDL2 from controls, highlighting its promise as a possible biomarker in HDL2 research.
HolmesSEO’HearnERosenblattA, et al.A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease–like 2. Nat Genet2001; 29: 377–378.
2.
MargolisRLO’HearnERosenblattA, et al.A disorder similar to Huntington’s disease is associated with a novel CAG repeat expansion. Ann Neurol2001; 50: 373–380.
3.
AndersonDGWalkerRHConnorM, et al.A systematic review of the Huntington disease-like 2 phenotype. J Huntingtons Dis2017; 6: 37–46.
4.
AndersonDGFerreira-CorreiaARodriguesFB, et al.Comparison of the Huntington’s disease like 2 and Huntington’s disease clinical phenotypes. Mov Disord Clin Pract2019; 6: 302–311.
5.
AndersonDGHaagensenMFerreira-CorreiaA, et al.Emerging differences between Huntington’s disease-like 2 and Huntington’s disease: a comparison using MRI brain volumetry. Neuroimage Clin2019; 21: 101666.
6.
Ferreira-CorreiaAAndersonDGCockcroftK, et al.A comparison between the neurocognitive profile of Huntington disease-like 2 and Huntington disease: exploring the presence of double dissociations. Appl Neuropsychol Adult2022; 29: 223–233.
7.
Ferreira-CorreiaAAndersonDGCockcroftK, et al.The neuropsychological deficits and dissociations in Huntington disease-like 2: a series of case-control studies. Neuropsychologia2020; 136: 107238.
8.
Ferreira-CorreiaAKrauseAAndersonDG. The neuropsychiatry of Huntington disease-like 2: a comparison with Huntington’s disease. J Huntingtons Dis2020; 9: 325–334.
9.
KrauseAMitchellCEssopF, et al.Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype. Am J Med Genet B Neuropsychiatr Genet2015; 168: 573–585.
10.
KrauseAAndersonDGFerreira-CorreiaA, et al.Huntington disease-like 2: insight into neurodegeneration from an African disease. Nat Rev Neurol2024; 20: 36–49.
11.
PaulsenJSLangbehnDRStoutJC, et al.Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry2008; 79: 874.
12.
TabriziSJLangbehnDRLeavittBR, et al.Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol2009; 8: 791–801.
13.
RosengrenLEKarlssonJ-EKarlssonJ-O, et al.Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem1996; 67: 2013–2018.
14.
ScahillRIZeunPOsborne-CrowleyK, et al.Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol2020; 19: 502–512.
15.
JohnsonEBByrneLMGregoryS, et al.Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology2018; 90: e717–e723.
16.
RodriguesFBByrneLMTortelliR, et al.Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease. Sci Transl Med2020; 12: eabc2888.
17.
ByrneLMRodriguesFBJohnsonEB, et al.Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. Sci Transl Med2018; 10: eaat7108.
18.
ByrneLMRodriguesFBBlennowK, et al.Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol2017; 16: 601–609.
19.
GaetaniLBlennowKCalabresiP, et al.Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry2019; 90: 870.
20.
GreensteinPEVonsattelJ-PGMargolisRL, et al.Huntington’s disease like-2 neuropathology. Mov Disord2007; 22: 1416–1423.
21.
RudnickiDDPletnikovaOVonsattelJ-PG, et al.A comparison of Huntington disease and Huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol2008; 67: 366–374.
22.
TabriziSJFlowerMDRossCA, et al.Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol2020; 16: 529–546.
23.
TabriziSJScahillRIOwenG, et al.Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol2013; 12: 637–649.
24.
WilburnBRudnickiDDZhaoJ, et al.An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in huntington’s disease-like 2 mice. Neuron2011; 70: 427–440.
25.
SeixasAIHolmesSETakeshimaH, et al.Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. Ann Neurol2012; 71: 245–257.
